Entocort: A Targeted Corticosteroid for Inflammatory Bowel Disease > 일반게시판

Introduction

Entocort (budesonide) is a glucocorticosteroid with potent anti‑inflammatory properties, specifically designed to treat mild‑to‑moderate active Crohn’s disease affecting the ileum and/or ascending colon. Unlike conventional systemic corticosteroids (e.g., prednisone), Entocort undergoes extensive first‑pass hepatic metabolism, resulting in low systemic bioavailability (about 10–15%). This targeted delivery minimises typical steroid‑related side effects while effectively reducing intestinal inflammation. This report provides a concise overview of Entocort’s pharmacology, clinical applications, efficacy, safety profile, and place in therapy.

Pharmacology and Formulation

Budesonide is a non‑halogenated corticosteroid with high affinity for the glucocorticoid receptor. Entocort is formulated as a pH‑ and time‑dependent release oral capsule containing enteric‑coated granules. The coating dissolves at pH above 5.5, releasing budesonide in the distal ileum and ascending colon – the most common sites of Crohn’s disease activity. Once absorbed, budesonide undergoes extensive first‑pass metabolism by cytochrome P450 3A4 (CYP3A4) in the liver, generating metabolites with negligible glucocorticoid activity. This "topical" effect within the gut lumen reduces systemic exposure, making Entocort a "locally acting" corticosteroid.

Indications and Dosing

Entocort is approved for inducing remission in adults with mild‑to‑moderate active Crohn’s disease involving the ileum and/or ascending colon. The standard dose is 9 mg once daily for up to 8 weeks. Tapering is not strictly required, but some clinicians gradually reduce the dose (e.g., to 6 mg for 2–4 weeks) to minimise adrenal suppression. It is not indicated for maintenance of remission in Crohn’s disease; prolonged use (>8 weeks) is not recommended due to potential glucocorticoid‑related adverse effects and lack of sustained benefit. Additionally, budesonide is used off‑label for other inflammatory bowel conditions, such as microscopic colitis and ulcerative colitis (in rectal foam or enema formulations), but the oral capsules are primarily for Crohn’s disease.

Efficacy in Clinical Trials

Multiple randomised controlled trials have demonstrated Entocort’s superiority over placebo for (Smashclub.es) inducing remission in active Crohn’s disease. The pivotal studies (e.g., Greenberg et al., 1994; Rutgeerts et al., 1996) showed that 9 mg/day of Entocort achieved clinical remission rates of 50–60% after 8 weeks, compared to 30–40% for mesalamine and 40–50% for prednisolone. Importantly, Entocort was as effective as conventional corticosteroids in the short term but with significantly fewer systemic side effects (e.g., moon face, acne, adrenal suppression). However, Entocort is less effective for severe disease or disease proximal to the ileum (e.g., jejunum or stomach) because of its limited systemic absorption and targeted release. For patients with exclusively colonic Crohn’s disease, data are conflicting, and systemic corticosteroids may be preferred.

Safety and Adverse Effects

The major advantage of Entocort is its reduced systemic exposure. In clinical trials, the incidence of typical corticosteroid‑related adverse events (e.g., insomnia, mood changes, hyperglycemia, osteoporosis) is notably lower than with prednisone. Common side effects include headache, nausea, dyspepsia, and mild HPA‑axis suppression (clinically significant adrenal insufficiency is rare but possible). Long‑term use (>3 months) can lead to bone mineral density loss, but this risk is lower than with systemic steroids. Caution is required in patients with active infections, glaucoma, or diabetes. Drug interactions are possible with CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice) that can increase systemic exposure. Adrenal suppression may occur after prolonged treatment, so stress‑dose steroid coverage may be needed during surgery or severe illness if the patient has recently taken Entocort.

Comparison with Other Therapies

Entocort occupies a unique niche between mesalamine (5‑ASA) agents and systemic corticosteroids. Mesalamine is less effective for Crohn’s disease than for ulcerative colitis, making Entocort a suitable first‑line corticosteroid option for mild‑to‑moderate ileocecal Crohn’s disease. Compared to budesonide Multi‑Matrix (MMX) formulation, Entocort EC (enteric‑coated) is more commonly used in North America; both have similar efficacy and safety. For moderately‑severe disease, systemic corticosteroids (prednisone) or biologics (anti‑TNF, anti‑integrin) are generally preferred. Entocort is not recommended for maintenance of remission; studies have shown that continued use beyond 8–12 weeks does not reduce relapse rates and increases the risk of steroid‑related complications.

Clinical Pearls

• Administer Entocort in the morning with breakfast (food may enhance absorption).
  
• Avoid concurrent use of potent CYP3A4 inhibitors unless absolutely necessary.
  
• Monitor for signs of hypercorticism if used for extended periods (e.g., >8 weeks).
  
• For patients who cannot taper systemic prednisone, switching to Entocort is sometimes attempted, but success is limited.
  
• Do not use Entocort for fistulising or fibrostenotic Crohn’s disease (requires systemic or surgical approach).
  
  

Current guidelines (American College of Gastroenterology, European Crohn’s and Colitis Organisation) recommend budesonide as first‑line steroid therapy for mild‑to‑moderate active ileocecal Crohn’s disease. It is an alternative for patients who cannot tolerate mesalamine or who need a short course of steroids without the systemic burden. For other types of IBD (e.g., ulcerative colitis), rectal budesonide formulations (foam, enema) are available for distal disease, but oral budesonide (Entocort) has a limited role. In recent years, the availability of biosimilars and newer oral small molecules (e.g., ozanimod, upadacitinib) has expanded the therapeutic landscape, but Entocort remains a valuable, well‑tolerated option for induction of remission in selected patients.

Conclusion

Entocort (budesonide) is an effective, targeted corticosteroid for inducing remission in mild‑to‑moderate Crohn’s disease of the ileum and ascending colon. Its favourable pharmacokinetic profile – high first‑pass metabolism – results in fewer systemic side effects compared to traditional corticosteroids. Short‑term use (up to 8 weeks) is safe and well tolerated. For maintenance, alternative therapies are recommended. Clinicians should weigh the benefits of local action against the need for systemic control in more extensive or severe disease. Overall, Entocort represents a significant advance in the treatment of inflammatory bowel disease, providing steroid efficacy with reduced toxicity.